Stay updated with breaking news from Performance Enzymes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ARK Investment Management LLC lowered its position in Codexis, Inc. (NASDAQ:CDXS – Get Rating) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,941,985 shares of the biotechnology company’s stock after selling 331,500 shares during the period. ARK […]
Codexis (NASDAQ:CDXS – Get Rating) and CN Energy Group. (NASDAQ:CNEY – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Earnings & Valuation This table compares Codexis and CN […]
Taylor Frigon Capital Management LLC trimmed its stake in Codexis, Inc. (NASDAQ:CDXS – Get Rating) by 18.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 199,868 shares of the biotechnology company’s stock after selling 45,106 shares during the quarter. Codexis accounts for about 2.0% of Taylor Frigon Capital Management LLC’s holdings, making the stock […]
Codexis, Inc. (NASDAQ:CDXS – Get Rating) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $16.48 and last traded at $16.55, with a volume of 4714 shares changing hands. The stock had previously closed at $16.97. Several brokerages have recently issued reports on CDXS. TheStreet lowered […]
Product revenues increased 101% to $10.2 million in Q1 (compared to $5.1 million in Q1 2020), driven by enzymes used to manufacture branded pharmaceutical products. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics.